Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs 10X Genomics Inc (TXG) Price & Performance

iShares S&P GSCI Commodity-Indexed Trust ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

iShares S&P GSCI Commodity-Indexed Trust ETF vs 10X Genomics Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.85, while 10X Genomics Inc trades at $42.61 (market cap $5.81B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares S&P GSCI Commodity-Indexed Trust ETF nearer its low. Which is the better fit depends on your goals.

GSGTXG
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$34.77$45.80
52-Week Low
$22.06$11.34
Market Cap
$5.81B
Enterprise Value
$5.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares S&P GSCI Commodity-Indexed Trust ETF

GSG trades at $31.00, up 1.57% today, with strong bullish technical signals from moving averages and ADX indicators, though RSI levels suggest overbought conditions. The stock's support and resistance levels are consolidated at $31.00, indicating a pivotal price point. Recent news highlights commodities as a key market theme, which may benefit GSG given its focus.

The outlook for GSG is cautiously optimistic, driven by bullish technical trends and positive sentiment around commodities. Risks include potential overbought corrections and reliance on commodity market stability. Investment opportunities hinge on sustained commodity demand, but investors should monitor earnings fundamentals for validation.

10X Genomics Inc

10x Genomics (TXG) trades at $42.56, down 7.07% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company demonstrates strong revenue stability around $640M annually and improving profitability trends, with net losses narrowing significantly from -$255M in 2023 to -$44M in 2025. Recent strategic moves include the Proteintech Genomics acquisition and Cleveland Clinic collaboration to expand multiomics capabilities.

While the company shows promising margin improvement and strategic growth initiatives, investors face valuation concerns with elevated P/S and EV/EBITDA ratios. The mixed analyst sentiment (45% buy, 50% hold) and consensus price target below current levels suggest cautious optimism. Key risks include ongoing profitability challenges and competitive pressures in the life sciences tools market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares S&P GSCI Commodity-Indexed Trust ETF

GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.

Read more on GSG

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG